
A study revealed that high out-of-pocket costs for rifaximin, a medication used for hepatic encephalopathy, lead to medication non-adherence among individuals with scarred livers. Highlights the impact on patient outcomes, including falls and hospitalizations. The study encompassed 6,800 cirrhosis patients, indicating younger age, metastatic cancer, and depression as factors for non-compliance. Clinicians and policymakers are urged to prioritize patient medication adherence in liver disease management.
Like
Save
Share